Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01021748

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Locally Advanced or Metastatic Solid Tumors Clinical Trial

Official title:
A Phase I Study of Oral MK-2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors

Clinical Trial Summary

This study will investigate the safety and tolerability of combination therapy with MK-2206 and AZD6244 (selumetinib) and determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) for this drug combination in the treatment of participants with locally advanced or metastatic solid tumors. Preliminary efficacy data will also be collected.

The primary hypotheses for this study are that: 1) the Dose-limiting Toxicities (DLTs) observed in participants with locally advanced or metastatic solid tumors after administration of combination therapy with MK-2206 and AZD6244 will be dose-dependent and allow for identification of the MTD, and 2) oral administration of combination therapy with MK-2206 and AZD6244 to participants with advanced solid tumors will be generally well-tolerated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Locally Advanced or Metastatic Solid Tumors
Clinical Trial Details
NCT number NCT01021748
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 1
Start date November 23, 2009
Completion date July 16, 2014
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04564417 - First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04511845 - A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Phase 1
Active, not recruiting NCT04128423 - Study of AMV564 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT05012618 - A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Phase 1
Recruiting NCT05581004 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03736850 - Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05137275 - Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors Early Phase 1
Completed NCT01713036 - Oral Bioavailability and Mass Balance Trial With Pimasertib Phase 1
Recruiting NCT05116709 - Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors Phase 1
Recruiting NCT05102214 - HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06349811 - A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03478995 - Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06293651 - Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06328439 - A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05830539 - IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients Phase 1/Phase 2
Recruiting NCT05205109 - A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05360381 - HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03150810 - Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05957471 - Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors Phase 1
Terminated NCT03565991 - Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors Phase 2